When Sequencing Is No Longer the Bottleneck: From Episodic Genomic Testing to Persistent Genomic Infrastructure

Article

For much of the past two decades, precision medicine has been defined by a single challenge: obtaining genomic information. The Human Genome Project, next-generation sequencing, and the rapid decline in sequencing costs transformed what was once a scientific achievement into an increasingly routine component of clinical care. Today, patients with many cancers undergo genomic profiling as a standard part of diagnosis, pharmacogenomic testing guides medication selection, and inherited disease panels have become commonplace. In many ways, precision medicine has succeeded in solving its original problem. The rate-limiting step is no longer sequencing. Instead, the new bottleneck is understanding. As genomic data become ubiquitous, the fundamental question has shifted from "Can we sequence the genome?" to "How do we continuously transform genomic information into better clinical decisions?" Singapore's National Precision Medicine Programme provides one of the clearest examples of this transition. Announced in 2017, the initiative began by building an Asian genomic reference dataset through the sequencing of 10,000 individuals. It subsequently expanded to more than 100,000 participants, integrating genomic, clinical, environmental, and lifestyle data. The program's long-term vision was articulated in a 2023 Nature Genetics article describing a national strategy that extends far beyond genomic discovery. Wong E, Bertin N, Hebrard M, et al.; SG10K_Health Consortium.The Singapore National Precision Medicine Strategy.Nature Genetics.2023;55(2):178–186. doi:10.1038/s41588-022-01274-x. Today, that vision is entering its most ambitious phase. Rather than asking whether genomic information can improve healthcare, Singapore is testing how genomic information can become part of healthcare itself. Phase III of the program seeks to integrate genomic medicine into routine clinical practice across the national health system, enrolling hundreds of thousands of additional participants while evaluating clinical outcomes, implementation strategies, physician workflows, and health economics. This represents a profound conceptual shift—from episodic genomic testing to persistent genomic infrastructure. Traditionally, genomic testing has been episodic. A patient develops lung cancer, a biopsy is performed, sequencing is ordered, a report is generated, and the information is used to guide a treatment decision. The process begins with disease and ends with a clinical report. Persistent genomic infrastructure turns that model upside down. In this paradigm, an individual's genome is sequenced once and becomes a permanent component of the medical record. As scientific knowledge advances, that same genomic dataset can be reinterpreted repeatedly throughout life. A pharmacogenomic variant may influence drug selection today. Years later, newly discovered evidence may identify an inherited cancer predisposition that changes screening recommendations. A variant previously classified as having uncertain significance may later become clinically actionable without the patient ever undergoing another sequencing test. The genome remains unchanged. Our understanding evolves. This distinction has profound implications. The value of genomic medicine no longer lies solely in generating data but in maintaining a healthcare system capable of continuously integrating new biological knowledge into clinical decision-making. The implications extend well beyond genomics. Precision medicine increasingly depends on the ability to connect molecular biology, diagnostics, therapeutics, clinical evidence, artificial intelligence, and patient care into a continuously learning ecosystem. As biological knowledge expands exponentially, the greatest challenge will not be discovering new information but organizing it in ways that remain interpretable, current, and clinically useful. This is why the future of precision medicine will be defined less by sequencing technology and more by knowledge infrastructure. Sequencing has become a commodity. Understanding has become the scarce resource. The next era of precision medicine will belong to healthcare systems that can continuously learn, adapt, and transform biological discovery into better patient care. Singapore's National Precision Medicine Programme offers an early blueprint for that future—and suggests that the greatest innovation in genomic medicine may not be reading the genome itself, but building the systems that allow its meaning to evolve throughout a patient's lifetime. Reference Wong E, Bertin N, Hebrard M, et al.; SG10K_Health Consortium.The Singapore National Precision Medicine Strategy.Nature Genetics.2023;55(2):178–186. doi:10.1038/s41588-022-01274-x.